NEUROCRINE BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
NEUROCRINE BIOSCIENCES INC (NBIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 1.00 million shares for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2018-11-05
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-09-30 was 0.00 shares.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-06-30 was 200.00K shares, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2018-03-31 was 800.00K shares, a 42.86% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2017-12-31 was 207.00K shares, a 168.83% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2017 was 1.81M shares, a 67.78% increase from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2016 was 1.08M shares, a 7.08% decline from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 1.16M shares, a 6.43% increase from fiscal 2014.
- NEUROCRINE BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 1.09M shares, a 41.25% increase from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 200.00K shares derived: sum of 2 quarters · filed 2018-11-05 | 1.00M shares 10-Q · filed 2018-11-05 | 1.21M shares derived: sum of 4 quarters · filed 2018-11-05 |
| 2018-06-30 | 200.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | 1.00M shares 10-Q · filed 2018-07-31 | 1.21M shares derived: sum of 3 quarters · filed 2018-07-31 | 1.21M shares derived: sum of 4 quarters · filed 2018-11-05 |
| 2018-03-31 | 800.00K shares 10-Q · filed 2018-04-30 | 1.01M shares derived: sum of 2 quarters · filed 2018-04-30 | 1.01M shares derived: sum of 3 quarters · filed 2018-11-05 | 1.21M shares derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-12-31 | 207.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | 207.00K shares derived: sum of 2 quarters · filed 2018-11-05 | 407.00K shares derived: sum of 3 quarters · filed 2018-11-05 | 1.81M shares 10-K · filed 2018-02-13 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | 200.00K shares derived: sum of 2 quarters · filed 2018-11-05 | 1.60M shares 10-Q · filed 2018-11-05 | 1.68M shares derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | 200.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | 1.60M shares 10-Q · filed 2018-07-31 | 1.68M shares derived: sum of 3 quarters · filed 2018-07-31 | 1.78M shares derived: sum of 4 quarters · filed 2018-07-31 |
| 2017-03-31 | 1.40M shares 10-Q · filed 2018-04-30 | 1.48M shares derived: sum of 2 quarters · filed 2018-04-30 | 1.58M shares derived: sum of 3 quarters · filed 2018-04-30 | 1.78M shares derived: sum of 4 quarters · filed 2018-04-30 |
| 2016-12-31 | 77.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | 177.00K shares derived: sum of 2 quarters · filed 2018-02-13 | 377.00K shares derived: sum of 3 quarters · filed 2018-02-13 | 1.08M shares 10-K · filed 2018-02-13 |
| 2016-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | 300.00K shares derived: sum of 2 quarters · filed 2017-11-01 | 1.00M shares 10-Q · filed 2017-11-01 | 1.06M shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | 200.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | 900.00K shares 10-Q · filed 2017-08-03 | 959.00K shares derived: sum of 3 quarters · filed 2018-02-13 | 1.06M shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | 700.00K shares 10-Q · filed 2017-05-09 | 759.00K shares derived: sum of 2 quarters · filed 2018-02-13 | 859.00K shares derived: sum of 3 quarters · filed 2018-02-13 | 1.16M shares derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | 59.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | 159.00K shares derived: sum of 2 quarters · filed 2018-02-13 | 459.00K shares derived: sum of 3 quarters · filed 2018-02-13 | 1.16M shares 10-K · filed 2018-02-13 |
| 2015-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | 400.00K shares derived: sum of 2 quarters · filed 2016-11-02 | 1.10M shares 10-Q · filed 2016-11-02 | 1.29M shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | 300.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | 1.00M shares 10-Q · filed 2016-08-03 | 1.19M shares derived: sum of 3 quarters · filed 2017-02-14 | 1.19M shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | 700.00K shares 10-Q · filed 2016-05-05 | 889.00K shares derived: sum of 2 quarters · filed 2017-02-14 | 889.00K shares derived: sum of 3 quarters · filed 2017-02-14 | 989.00K shares derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | 189.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | 189.00K shares derived: sum of 2 quarters · filed 2017-02-14 | 289.00K shares derived: sum of 3 quarters · filed 2017-02-14 | 1.09M shares 10-K · filed 2017-02-14 |
| 2014-09-30 | 0.00 shares 10-Q · filed 2014-11-04 | 100.00K shares derived: sum of 2 quarters · filed 2015-07-29 | 900.00K shares 10-Q · filed 2015-10-29 | 871.00K shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | 900.00K shares 10-Q · filed 2015-07-29 | 871.00K shares derived: sum of 3 quarters · filed 2016-02-11 | 871.00K shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | 800.00K shares 10-Q · filed 2015-04-30 | 771.00K shares derived: sum of 2 quarters · filed 2016-02-11 | 771.00K shares derived: sum of 3 quarters · filed 2016-02-11 | 871.00K shares derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | -29.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | -29.00K shares derived: sum of 2 quarters · filed 2016-02-11 | 71.00K shares derived: sum of 3 quarters · filed 2016-02-11 | 771.00K shares 10-K · filed 2016-02-11 |
| 2013-09-30 | 0.00 shares 10-Q · filed 2014-11-04 | 100.00K shares derived: sum of 2 quarters · filed 2014-11-04 | 800.00K shares 10-Q · filed 2014-11-04 | 846.00K shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | 800.00K shares 10-Q · filed 2014-08-06 | 846.00K shares derived: sum of 3 quarters · filed 2015-02-09 | 846.00K shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-03-31 | 700.00K shares 10-Q · filed 2014-05-01 | 746.00K shares derived: sum of 2 quarters · filed 2015-02-09 | 746.00K shares derived: sum of 3 quarters · filed 2015-02-09 | 846.00K shares derived: sum of 4 quarters · filed 2015-02-09 |
| 2012-12-31 | 46.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-09 | 46.00K shares derived: sum of 2 quarters · filed 2015-02-09 | 146.00K shares derived: sum of 3 quarters · filed 2015-02-09 | 1.45M shares 10-K · filed 2015-02-09 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | 100.00K shares derived: sum of 2 quarters · filed 2013-10-29 | 1.40M shares 10-Q · filed 2013-10-29 | 1.41M shares derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | 100.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | 1.40M shares 10-Q · filed 2013-07-26 | 1.41M shares derived: sum of 3 quarters · filed 2014-02-11 | 2.85M shares derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | 1.30M shares 10-Q · filed 2013-05-02 | 1.30M shares derived: sum of 2 quarters · filed 2014-02-11 | 2.75M shares derived: sum of 3 quarters · filed 2014-02-11 | |
| 2011-12-31 | 5.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | 1.45M shares derived: sum of 2 quarters · filed 2014-02-11 | 1.60M shares 10-K · filed 2014-02-11 | |
| 2011-09-30 | 1.45M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | 1.60M shares 10-Q · filed 2012-10-31 | ||
| 2011-06-30 | 155.00K shares 10-Q · filed 2012-07-31 | |||
| 2010-12-31 | 2.02M shares 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |